Q3 2025

Bio-Techne Delivers Strong Q3 Performance Amidst Uncertainty, Eyes Future Growth in Core Reagents and Cell Therapy Markets

TECH

Bio-Techne Delivers Strong Q3 Performance Amidst Uncertainty, Eyes Future Growth in Core Reagents and Cell Therapy Markets

Bio-Techne, a leading life science company, has reported a strong third quarter performance, with 6% organic revenue growth despite operating in a relatively uncertain macro environment. According to Kim Kelderman, President and Chief Executive Officer, the company delivered yet another strong quarter with an emphasis on profitability, driven by operational

By Aisha Goldstein
Jack Henry & Associates Shines in Q3 2025 with 7% Revenue Growth and 207 Basis Point Margin Expansion

JKHY

Jack Henry & Associates Shines in Q3 2025 with 7% Revenue Growth and 207 Basis Point Margin Expansion

Jack Henry & Associates, Inc. recently reported its third quarter fiscal year 2025 results, showcasing solid overall performance despite macroeconomic concerns and softening nonstrategic revenue. The company's commitment to a people-first culture, service excellence, technology innovation, and clear strategy backed by consistent execution continues to differentiate it in

By Anton Sventee